Pancragen
Peptide Bioregulator
Also known as Lys-Glu-Asp-Trp (KEDW)
Pancragen is the tetrapeptide Lys-Glu-Asp-Trp, studied in research on pancreatic tissue models and endocrine function in ageing.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Pancragen is the tetrapeptide Lys-Glu-Asp-Trp, studied in research on pancreatic tissue models and endocrine function in ageing.
Experimental work examines short-peptide effects on pancreatic cell activity in rodent and primate models.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for the 20mg lot is being finalised and will be published here as soon as the lab returns it.
Pancragen is one of the more thoroughly documented tissue-directed tetrapeptides. Published studies have examined the biological activity of the Lys-Glu-Asp-Trp sequence, its influence on functional activity of pancreatic cells during ageing, and endocrine endpoints in old monkeys.
Additional work characterized functional morphology of the pancreas in rodent diabetes models, and the sequence appears in reviews of short-peptide gene regulation and cell differentiation.
Pancragen was characterized within the Russian peptide-bioregulator research programme as the tissue-directed peptide associated with pancreatic models.
Subsequent work extended from rodent studies into non-human primate endocrine research, making it comparatively well covered for this compound class.
Research into the KEDW sequence focuses on pancreatic cell function and endocrine endpoints during ageing. Frameworks evaluate functional morphology, insulin-axis activity, and short-peptide gene regulation under controlled preclinical conditions.
4 of the 4 areas below are addressed directly by a paper cited on this page.
Pancreatic tissue-culture and endocrine models
Addressed on this page by Khavinson 2012, Goncharova 2014. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, VKh. et al. (2012) — Tetrapeptide stimulates functional activity of the pancreatic cells in aging
- Goncharova, ND. et al. (2014) — Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys
Short-peptide gene-expression regulation
Addressed on this page by Khavinson 2016, Kvetnoi 2007, Khavinson 2010. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, VK. et al. (2016) — Short Peptides Regulate Gene Expression
- Kvetnoi, IM. et al. (2007) — Effect of tetrapeptide pancragene on functional morphology of the pancreas in rats with experimental diabetes mellitus
- Khavinson, VKh. et al. (2010) — Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide
Ageing and primate endocrine research
Addressed on this page by Goncharova 2014. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Goncharova, ND. et al. (2014) — Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys
Peptide-directed cell differentiation
Addressed on this page by Khavinson 2012, Khavinson 2010, Goncharova 2014. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, VKh. et al. (2012) — Tetrapeptide stimulates functional activity of the pancreatic cells in aging
- Khavinson, VKh. et al. (2010) — Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide
- Goncharova, ND. et al. (2014) — Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys
The references section of this page cites 5 primary papers published between 2007 and 2016 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Worth noting when weighing that record: roughly 60% of the citations here list Khavinson as lead author. A literature concentrated in one research group has not been independently replicated to the same degree as one drawn from many, and that is a real limitation on how far the findings can be generalised — regardless of how consistent the individual results look.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Pancragen, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Pancragen is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under pancreatic tissue-culture and endocrine models, short-peptide gene-expression regulation and ageing and primate endocrine research.
The 5 papers cited on this page, published between 2007 and 2016 (1 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented as having independent scientific backing.
Around 60% of the papers cited here list Khavinson as lead author. A literature concentrated in one research group has not been independently replicated to the degree its volume suggests, and that is a real limit on how far the findings generalise — however consistent the individual results appear.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Pancragen is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Pancragen in the United States through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
Pancragen is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 4 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (20mg / Single Vial, 20mg / 5-Pack, 20mg / 10-Pack available), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of Pancragen. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide
PubMedTetrapeptide stimulates functional activity of the pancreatic cells in aging
PubMedImpact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys
PubMedEffect of tetrapeptide pancragene on functional morphology of the pancreas in rats with experimental diabetes mellitus
PubMedRelated
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99